Shire, which is soon to be AbbVie, has finalized a deal with US biotech ArmaGen. The $225-million deal gives Shire worldwide commercialization rights to the experimental enzyme replacement therapy AGT-182, which could be used to treat what the firms describe in a statement as “the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome.”
Hunter syndrome is a rare disease in which the body can’t get rid of cellular waste. Around 1,200 patients have been diagnosed with the genetic disorder.
